I. Don’t think that is A given.. however the phase 1. Trials uskualy are ncot blinded so this is a Very good sign. After reading Yale announce it does seem Algernon has done what they may to protect IP .. This. Probably savers them a lot of ‘money..
I again direct the company to fill how anavex lead in funding clinical research